Clinical trials
Breast Cancer Screening and Diagnosis clinical trials
Below are recruiting breast cancer screening and diagnosis clinical trials, each written for real people, not researchers. We’re tracking 246 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07361562RecruitingPhase 1
Study of CGT4255 for advanced solid tumors with HER2 changes
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06111417Recruiting
Rapid BRCA1/2 test for newly diagnosed breast cancer patients
This study tests a new ultra-rapid genetic test for BRCA1/2 mutations in people recently diagnosed with breast cancer. It aims to see if the faster result helps doctors and patients make treatment decisions sooner.
DijonAges 18 years+ - NCT07832396Enrolling by invitation
Mammogram reminder study for women in Singapore
This study tests different ways to encourage women in Singapore to get a mammogram, which is an X-ray of the breast that helps find cancer early. If you are due for a mammogram, this study may help you get screened sooner.
SingaporeAges 50–69 - NCT07168993Recruiting
Sputum test for lung cancer in high-risk people with lung nodules
This study tests a new, non-invasive test that looks at a sputum (phlegm) sample to see if it can detect lung cancer in people who have a lung nodule. The test might help avoid more invasive procedures and help doctors decide next steps.
Palo Alto, CaliforniaAges 50–80 - NCT06817525RecruitingPhase 2
Chemo and immunotherapy before surgery for early triple-negative breast cancer
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
Zhengzhou, HenanAges 18–65 - NCT04819243RecruitingPhase 2
Test a BRCA-targeted drug plan for advanced ER-positive breast cancer
This Phase 2 study tests how well a treatment plan using palbociclib followed by talazoparib (and possibly atezolizumab) works in certain people with advanced ER-positive breast cancer. It may help by targeting cancer biology linked to BRCA/HRD changes and by strengthening how the cancer is controlled.
Seoul, Gannam-guAges 19 years+ - NCT07283107Enrolling by invitation
Increasing mammogram rates in Singaporean women
This trial tests different ways to encourage women in Singapore to get a mammogram (a breast X-ray to check for cancer early). You may be eligible if you are a Singaporean citizen aged 50–69, use the NUHS app, and have either never had a mammogram or are overdue for your next one.
SingaporeAges 50–69 - NCT07203378RecruitingPhase 2
Exercise program for energy and zest on Enhertu
This study tests whether a supervised exercise program can help reduce fatigue and improve energy for people with breast cancer who are taking the drug Enhertu. You would do both aerobic and resistance exercises over several weeks.
Salt Lake City, UtahAges 18 years+ - NCT07070765Recruiting
Study on dapagliflozin to protect the heart during breast cancer chemo
This trial tests if a heart-protecting drug called dapagliflozin can help prevent heart damage in breast cancer patients receiving a type of chemotherapy called anthracycline. It may be an option if you have low to medium heart risk factors.
Aberdeen, AberdeenshireAges 18–70 - NCT06993844RecruitingPhase 1/Phase 2
Study of ETX-636 for advanced solid tumors with PIK3CA mutation
This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Newport Beach, CaliforniaAges 18 years+ - NCT06923527RecruitingPhase 2
Testing ctDNA to start elacestrant in early breast cancer
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
New Haven, ConnecticutAges 18 years+ - NCT06908928RecruitingPhase 1
Study of Bulumtatug Fuvedotin for advanced triple-negative breast cancer
This study tests a new drug called bulumtatug fuvedotin for people with triple-negative breast cancer that has spread or come back. It's for those who have already tried certain other treatments, including a taxane and a specific type of antibody-drug conjugate.
Duarte, CaliforniaAges 18 years+ - NCT06700070RecruitingEarly Phase 1
Testing a microdose drug in solid tumors before surgery
This study tests a tiny amount of an experimental drug (PBA-0111) injected directly into tumors that will be surgically removed later. The goal is to see how the drug affects the tumor tissue, which may help guide future treatments for solid tumors like head and neck cancer, certain sarcomas, or triple-negative breast cancer.
Shreveport, LouisianaAges 18 years+ - NCT06371274Recruiting
Oral vitamin A drug plus immunotherapy for advanced triple-negative breast cancer
This trial tests a combination of an oral vitamin A-based drug (all-trans retinoic acid) and an immunotherapy (toripalimab) for people with advanced triple-negative breast cancer that hasn't responded to at least two prior treatments. The goal is to see if this combination can shrink or control the cancer.
Hangzhou, Zhejiang Province, P.R. ChinaAges 18 years+ - NCT06645808RecruitingEarly Phase 1
PET imaging study for various solid tumors
This study uses a special PET scan to see if a new imaging agent can help find and monitor certain solid tumors. It is for people with colon, rectal, sarcoma, breast, lung, head and neck, esophageal, stomach, pancreas, bladder cancers, or glioblastoma who have had standard treatment before surgery.
Groningen, Provincie GroningenAges 18 years+ - NCT06481956Enrolling by invitationPhase 2
T-DM1 plus a CDK4/6 inhibitor (ribociclib) for HER2-positive breast cancer
This clinical trial tests a combination of two targeted therapies for people with HER2-positive breast cancer that has spread or come back. The goal is to see if adding ribociclib to T-DM1 is safe and effective after other treatments have been used.
Hangzhou, ZhejiangAges 18–75 - NCT06427226RecruitingPhase 2
Testing dapagliflozin to protect the heart during breast cancer chemo
This trial tests whether a daily pill called dapagliflozin can help protect the heart from damage caused by doxorubicin chemotherapy in people being treated for early-stage breast cancer. If you are starting doxorubicin and have a healthy heart, this might lower your risk of heart problems later.
Alexandria, Bab SharqiAges 18–65 - NCT06439771RecruitingPhase 2
Testing YL202 for advanced breast cancer
This trial tests a new drug called YL202 for people with advanced breast cancer. It is for those who have already tried certain targeted treatments (HER2 or TROP2 antibody-drug conjugates) and they stopped working. The goal is to see if YL202 can help shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06353997RecruitingPhase 2
Neoadjuvant INBRX-106 with pembrolizumab for early-stage triple-negative breast cancer
This trial tests whether adding an experimental drug called INBRX-106 to the standard immunotherapy (pembrolizumab) and chemotherapy before surgery can improve outcomes for patients with early-stage triple-negative breast cancer. The goal is to shrink the tumor and potentially reduce the risk of the cancer coming back.
Los Angeles, CaliforniaAges 18 years+ - NCT06107686RecruitingPhase 2
YL202 for advanced solid tumors
This trial tests a new drug called YL202 for people with advanced solid tumors (cancers that have spread or cannot be removed). It aims to see if the drug can shrink tumors or slow cancer growth. You may be able to join if you have certain types of cancer, have not had a previous HER3 treatment, and can provide a tumor sample.
Hefei, AnhuiAges 18–75 - NCT05559164RecruitingPhase 2
Statins to protect the heart during HER2 breast cancer treatment
This trial tests whether a cholesterol medicine (a statin) can lower the risk of heart damage in people receiving HER2-targeted breast cancer therapy. If you qualify, you may be given a statin and followed with heart tests and blood work to watch for safety and benefit.
Elizabeth, New JerseyAges 18 years+ - NCT05768139RecruitingPhase 1/Phase 2
Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
Los Angeles, CaliforniaAges 18 years+ - NCT07114601RecruitingPhase 1
Study of LY4257496 for people with GRPR-positive solid tumors
This trial tests a new drug, LY4257496, in people with certain types of cancer that have a protein called GRPR on their cells. The study aims to see if the drug can help shrink tumors or slow the cancer's growth.
Duarte, CaliforniaAges 18 years+ - NCT07035587Recruiting
A blood test to detect multiple cancers and monitor leftover tumors after treatment
This trial uses a blood test to find early signs of cancer or leftover tumor cells after treatment. It may help people with certain cancers or those with non-cancerous growths understand their condition better.
SeoulAges 19 years+
Hear when a new Breast Cancer Screening and Diagnosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer screening and diagnosis?
- Yes. Clin2 currently lists 246 recruiting breast cancer screening and diagnosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer screening and diagnosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer screening and diagnosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.